ENOVATE BIOLIFE PRIVATE LIMITED – Trademark Portfolio
Entity Type: 24
ENOVATE BIOLIFE PRIVATE LIMITED holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered and 2 are pending. Notable registered marks include X ENXTRA. The owner is based in MUMBAI, MAHARASHTRA.
203, MORYA LANDMARK 1, NEW LINK ROAD
ANDHERI WEST
MUMBAI, MAHARASHTRA 400053 , IN
Showing of trademarks Trademarks
Trademark Classifications
ENOVATE BIOLIFE PRIVATE LIMITED's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does ENOVATE BIOLIFE PRIVATE LIMITED have?
ENOVATE BIOLIFE PRIVATE LIMITED has 4 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 pending, 1 cancelled.
What trademark classes does ENOVATE BIOLIFE PRIVATE LIMITED file in?
ENOVATE BIOLIFE PRIVATE LIMITED files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are ENOVATE BIOLIFE PRIVATE LIMITED's most well-known trademarks?
ENOVATE BIOLIFE PRIVATE LIMITED's registered trademark portfolio includes well-known marks such as X ENXTRA. These are among 1 currently registered trademark in the portfolio.
What is ENOVATE BIOLIFE PRIVATE LIMITED's trademark registration success rate?
ENOVATE BIOLIFE PRIVATE LIMITED has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 2 applications are pending review.